HCG vs Kisspeptin.

Human chorionic gonadotropin (HCG) is a naturally occurring glycoprotein hormone produced by the placenta during pregnancy, and it is also manufactured as an FDA-approved injectable medicine. As a drug it is sold under brand names such as Pregnyl and Novarel (purified from urine) and Ovidrel (recombinant). It is used in reproductive and endocrine medicine rather than as a research peptide. Because its activity closely mimics luteinizing hormone (LH), it is used to stimulate the gonads in both males and females.

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene and cleaved from a 145-amino-acid precursor into fragments named for their length (kisspeptin-54, -14, -13, and -10), all sharing a common C-terminal decapeptide that confers biological activity. Originally identified as the product of a metastasis-suppressor gene (and so called "metastin"), it is now recognized chiefly as the master upstream regulator of the reproductive neuroendocrine axis. It is an endogenous human peptide, not a designer or synthetic-only compound, and acts on a specific G-protein-coupled receptor.

HCG shares strong structural similarity with LH and binds the LH/HCG receptor, effectively acting as an LH agonist. In males, this stimulates the Leydig cells of the testes to produce testosterone and can support spermatogenesis; in prepubertal boys with cryptorchidism it can promote testicular descent. In females undergoing fertility treatment, HCG triggers final oocyte maturation and ovulation after follicular development. These direct effects on the gonads are the basis for its approved clinical uses.

Kisspeptin signals through the receptor KISS1R (formerly GPR54), a Gq/11-coupled GPCR expressed densely on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. Binding triggers phospholipase-C signaling that depolarizes GnRH neurons and stimulates pulsatile GnRH release into the hypophyseal portal system, which in turn drives pituitary secretion of luteinizing hormone (LH) and, more modestly, follicle-stimulating hormone (FSH). Kisspeptin neurons in the arcuate nucleus (co-expressing neurokinin B and dynorphin, the "KNDy" neurons) are thought to constitute the GnRH pulse generator and to relay sex-steroid feedback, while a population in the anteroventral periventricular region mediates the estrogen-driven LH surge. Beyond the hypothalamic-pituitary-gonadal (HPG) axis, KISS1R is expressed in limbic and other brain regions, providing a plausible substrate for effects on sexual and emotional processing.

HCG has decades of established clinical use, and its FDA-approved indications are supported by its long regulatory and prescribing history rather than by a single pivotal trial. Approved uses include prepubertal cryptorchidism not due to anatomic obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in carefully selected infertile women as part of assisted reproduction. In men, it is also used clinically to preserve testicular function and fertility, though some such uses are off-label. Much of this evidence base predates modern trial standards, so the supporting literature is a mixture of older controlled studies, registry and clinic series, and specialty guidance rather than large contemporary randomised trials with adjudicated endpoints. Notably, the FDA-approved labeling explicitly states there is no substantial evidence that HCG is effective for weight loss or fat redistribution, and it is not approved for weight loss. The weight-loss claim has actually been tested. A criteria-based meta-analysis published in the British Journal of Clinical Pharmacology in 1995 assessed controlled trials of HCG for obesity under the Simeons regimen and concluded that the evidence did not support an effect of HCG on weight loss, fat distribution, hunger or wellbeing. Where weight loss was observed in such programs, it is attributable to the severe caloric restriction that accompanied the injections rather than to the hormone. This contrasts sharply with actual obesity pharmacotherapy, where agents such as GLP-1 receptor agonists were approved on the basis of large randomised, double-blind, placebo-controlled Phase 3 trials with prespecified weight endpoints, and in some cases dedicated cardiovascular outcome trials. HCG has no comparable evidence for weight management. Its efficacy and safety for its endocrine and fertility indications are well characterized in the drug label and clinical guidelines.

The strongest human evidence is genetic and physiological rather than therapeutic. In 2003 two groups (de Roux et al., PNAS; Seminara et al., NEJM) independently showed that loss-of-function mutations in GPR54/KISS1R cause normosmic idiopathic hypogonadotropic hypogonadism and absent puberty, firmly establishing the pathway's necessity for human reproduction; activating mutations conversely associate with precocious puberty. Controlled human administration studies, largely from the Dhillo/Abbara group at Imperial College London, have repeatedly shown that exogenous kisspeptin acutely raises LH (and to a lesser extent FSH) and that responsiveness varies across the menstrual cycle and with estradiol status (e.g., J Clin Endocrinol Metab 2012 and 2017). Functional-MRI studies in healthy men reported that kisspeptin modulates limbic brain activity to sexual and emotional stimuli (Comninos et al., J Clin Invest 2017; JCI Insight 2018 and 2020). However, kisspeptin remains investigational: it has been explored as a diagnostic and ovulation-triggering tool in fertility settings and studied in hypothalamic amenorrhea, but there are no large phase-3 efficacy trials and no approved kisspeptin drug, so claims of broad libido, fertility, or wellness benefit outrun the existing human data.

Recognized risks include ovarian hyperstimulation syndrome and increased chance of multiple pregnancy when used for ovulation induction, as well as injection-site reactions, headache, fatigue, mood changes, gynecomastia, and, rarely, arterial thromboembolism. HCG should not be used during pregnancy and requires medical supervision, particularly in patients with conditions sensitive to sex-steroid changes. Because HCG acts as an LH analogue, it raises endogenous sex-steroid production, so supervised use typically involves baseline and follow-up hormone testing, and in fertility settings ultrasound follicle monitoring and estradiol measurement precisely because ovarian hyperstimulation can escalate quickly and is occasionally severe. In males, prolonged stimulation can raise estradiol and affect the testosterone to estradiol balance, which is one reason clinical use is monitored rather than open-ended. Precocious puberty is a labelled concern when used in prepubertal boys. The labeling specifically warns against use for weight loss, including so-called 'HCG diet' regimens, which are not supported by evidence and may be paired with unsafe very-low-calorie dieting; the caloric restriction itself carries risks including nutrient deficiency, gallstones, electrolyte disturbance and loss of lean mass. A further hazard is supply. Over-the-counter, homeopathic and online HCG weight-loss products are unapproved, and injectable material obtained outside a pharmacy has no verified potency, purity or sterility, so unsupervised use adds an unregulated-product risk on top of a hormone that already needs clinical oversight.

In the controlled research settings published to date, single and short-term kisspeptin administration has generally been reported as well tolerated, with its central, on-mechanism effect being stimulation of the reproductive axis. Important unknowns dominate the picture: there are no long-term human safety data, repeated or continuous dosing can desensitize KISS1R signaling (a documented pharmacologic phenomenon), and effects necessarily depend on sex, sex-steroid milieu, and reproductive status. Because the pathway governs the HPG axis, off-label use carries theoretical risks to hormonal balance, ovulation timing, and fertility that have not been characterized outside monitored trials, and material sold as "research" kisspeptin has no assurance of identity, purity, or sterility. It is not an approved medicine for any consumer indication.

HCG is FDA-approved as a prescription injectable for specified endocrine and fertility indications (e.g., Pregnyl, Novarel, Ovidrel). The FDA has stated that HCG is not approved and lacks substantial evidence for weight loss, and over-the-counter 'homeopathic' HCG weight-loss products are considered unapproved and illegal. It is a prescription-only medicine that requires clinical oversight.

Kisspeptin is investigational/research-use-only: as of 2026 there is no FDA-approved kisspeptin product, and human use has occurred under research protocols (e.g., as an experimental fertility and diagnostic agent), not as an approved drug. It is not a controlled substance and is not specifically a WADA-prohibited compound, but its regulatory status as an unapproved peptide means it is not legally marketed for human treatment.